ロード中...
Checkpoint immunotherapy in head and neck cancers
Checkpoint inhibitors have recently gained FDA approval for the treatment of cisplatin-resistant recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) by outperforming standard of care chemotherapy and inducing durable responses in a subset of patients. These monoclonal antibodies u...
保存先:
| 出版年: | Cancer Metastasis Rev |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694874/ https://ncbi.nlm.nih.gov/pubmed/28836124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-017-9694-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|